Myelodysplastic Syndromes with 5q Deletion
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndromes with 5q Deletion.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-05-22FDA Approved: LENALIDOMIDE — Original Application (Devatis Inc.)
FDA approved a generic lenalidomide under the original application from Devatis Inc., enabling market access for this established cancer the…
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Alvogen, Inc.)
FDA approved Alvogen, Inc.'s original Abbreviated New Drug Application for a generic lenalidomide product (ANDA 210480).
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (EXELAN PHARMACEUTICALS INC.)
FDA approves a generic lenalidomide product from Exelan Pharmaceuticals under an original application. The drug is indicated for several hem…
-
FDA approval · 2021-08-05FDA Approved: LENALIDOMIDE — Supplemental Application (Teva Pharmaceuticals, Inc.)
FDA approved a supplemental application for lenalidomide by Teva Pharmaceuticals, approving changes related to the drug's use.